// Nathalie Allaman-Pillet 1 , Anne Oberson 1 , Daniel F. Schorderet 1 1 IRO - Institute for Research in Ophthalmology, CH-1950 Sion, Switzerland Correspondence to: Nathalie Allaman-Pillet, email: nathalie.allaman-pillet@irovision.ch Keywords: BIGH3, retinoblastoma, cancer, SV40-TAg-Rb mice Received: May 31, 2016 Accepted: December 24, 2016 Published: January 14, 2017 ABSTRACT BIGH3, a secreted protein of the extracellular matrix interacts with collagen and integrins on the cell surface. BIGH3 can have opposing functions in cancer, acting either as tumor suppressor or promoter by enhancing tumor progression and angiogenesis. In the eye, BIGH3 is expressed in the cornea and the retinal pigment epithelium and could impact on the development of retinoblastoma, the most common paediatric intraocular neoplasm. Retinoblastoma initiation requires the inactivation of both alleles of the RB1 tumor suppressor gene in the developing retina and tumor progression involves additional genomic changes. To determine whether BIGH3 affects retinoblastoma development, we generated a retinoblastoma mouse model with disruption of the Bigh3 genomic locus. Bigh3 silencing in these mice resulted in enhanced tumor development in the retina. A decrease in apoptosis is involved in the initial events of tumorigenesis, followed by an increased activity of the pro-survival ERK pathway as well as an upregulation of cyclin-dependent kinases (CDKs). Taken together, these data suggest that BIGH3 acts as a tumor suppressor in the retina.
